Restricted accessResearch articleFirst published online 2018-7-24
Prevalence and Determinants of Agonistic Autoantibodies Against α 1-Adrenergic Receptors in Patients Screened Positive for Dementia: Results from the Population-Based DelpHi-Study
There is a need to assess promising biomarkers for diagnosis and treatment response in real-life settings. Despite the important role of vascular risk factors, cardiovascular biomarkers have played a minor role in dementia research. Agonistic autoantibodies (agAAB) directed against G-protein-coupled receptors (GPCR) are discussed as modulators of pathology and clinical manifestation.
Objective:
1) Describe prevalence of agAAB directed against GPCR, especially agABB against α1-adrenergic receptors (α1-AR-agAAB) and agABB directed against β2-adrenergic receptors (β2-AR-agAAB) and 2) identify factors associated with agAAB in people with dementia during routine care.
Methods:
Blood samples and data from 95 subjects who screened positive for dementia from a primary care cohort, analyzed using an enzyme-linked immunosorbent assay (ELISA) for detecting agAAB. Sociodemographic and clinical data were assessed, and medical records checked.
Results:
In 40 (42%) samples, agAAB was detected, with n = 29 (31%) representing α1-AR-agAAB and n = 21 (22%) β2-AR-agAAB. There was no association between the presence of any antibody and a formal diagnosis of dementia. However, patients with coronary heart disease were more likely (OR = 4.23) to have α1-AR-agAAB than those without coronary heart disease. There were no associations between agAAB and age, sex, education, or cognitive impairment.
Discussion:
For the first time, we show that autoantibodies have a significant prevalence in people with dementia in a routine care setting. Previous findings were restricted to highly selective samples. We replicated the association between α1-AR-agAAB in patients with coronary heart diseases but were not able to find other factors associated with the presence of agAAB.
Alzheimer’s Disease International (2012) Dementia: A public health priorityWorld Health Organization (WHO), Geneva.
2.
PrinceM, BryceR, AlbaneseE, WimoA, RibeiroW, FerriCP (2013) The global prevalence of dementia: A systematic review and metaanalysis, Alzheimers Dement9, 63–75.
3.
BickelH (2001) [Dementia in advanced age: Estimating incidence and health care costs]. Z Gerontol Geriatr34, 108–115.
4.
Deutsche Gesellschaft für Psychiatrie Psychotherapie und Neurologie (DGPPN) (eds.)
(2017) [S3-guidelines: Dementia]Springer, Berlin.
5.
CavedoE, ListaS, KhachaturianZ, AisenP, AmouyelP, HerholzK, JackCRJr., SperlingR, CummingsJ, BlennowK, O’BryantS, FrisoniGB, KhachaturianA, KivipeltoM, KlunkW, BroichK, AndrieuS, de SchottenMT, ManginJF, LammertsmaAA, JohnsonK, TeipelS, DrzezgaA, BokdeA, ColliotO, BakardjianH, ZetterbergH, DuboisB, VellasB, SchneiderLS, HampelH (2014) The road ahead to cure Alzheimer’s disease: Development of biological markers and neuroimaging methods for prevention trials across all stages and target populations. J Prev Alzheimers Dis1, 181–202.
6.
AttemsJ, JellingerKA (2014) The overlap between vascular disease and Alzheimer’s disease–lessons from pathology. BMC Med12, 206.
7.
dela Torre JC (2002) Alzheimer disease as a vascular disorder: Nosological evidence. Stroke33, 1152–1162.
8.
ImtiazB, TolppanenAM, KivipeltoM, SoininenH (2014) Future directions in Alzheimer’s disease from risk factors to prevention, Biochem Pharmacol88, 661–670.
9.
DichgansM, WardlawJ, SmithE, ZietemannV, SeshadriS, SachdevP, BiesselsGJ, FazekasF, BenaventeO, PantoniL, De LeeuwFE, NorrvingB, MatthewsP, ChenC, MokV, DuringM, WhiteleyW, ShulerK, AlonsoA, BlackSE, BrayneC, ChabriatH, CordonnierC, DoubalF, DuzelE, EwersM, FrayneR, HachinskiV, IkramMA, JessenF, JouventE, LinnJ, O’BrienJ, van OostenbruggeR, MalikR, MazoyerB, SchmidtR, SposatoLA, StephanB, SwartzRH, VernooijM, ViswanathanA, WerringD, AbeK, AllanL, ArbaF, CollaborationV, DienerHC, DavisS, HankeyG, LeesKR, OvbiageleB, WeirC, BaeHJ, BathPM, BordetR, BretelerM, ChoiS, DearyI, DeCarliC, EbmeierK, FengL, GreenbergSM, IharaM, KalariaR, KimS, LimJS, LindleyRI, MeadG, MurrayA, QuinnT, RitchieC, SaccoR, Al-ShahiSalman R, SpriggN, SudlowC, ThomasA, van BoxtelM, vander Grond J, vander Lugt A, YangYH (2016) METACOHORTS for the study of vascular disease and its contribution to cognitive decline and neurodegeneration: An initiative of the Joint Programme for Neurodegenerative Disease Research. Alzheimers Dement12, 1235–1249.
10.
HempelP, HeinigB, JeroschC, DeciusI, KarczewskiP, KassnerU, KunzeR, Steinhagen-ThiessenE, BimmlerM (2016) Immunoadsorption of agonistic autoantibodies against alpha1-adrenergic receptors in patients with mild to moderate dementia, Ther Apher Dial20, 523–529.
DandelM, WallukatG, EnglertA, HetzerR (2013) Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension. Atheroscler Suppl14, 203–211.
13.
KarczewskiP, PohlmannA, WagenhausB, WisbrunN, HempelP, LemkeB, KunzeR, NiendorfT, BimmlerM (2012) Antibodies to the alpha1-adrenergic receptor cause vascular impairments in rat brain as demonstrated by magnetic resonance angiography. PLoS One7, e41602.
14.
KarczewskiP, HempelP, KunzeR, BimmlerM (2012) Agonistic autoantibodies to the alpha(1) -adrenergic receptor and the beta(2) -adrenergic receptor in Alzheimer’s and vascular dementia. Scand J Immunol75, 524–530.
15.
JahnsR, BoivinV, HeinL, TriebelS, AngermannCE, ErtlG, LohseMJ (2004) Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest113, 1419–1429.
16.
TeipelSJ, KellerF, ThyrianJR, StrohmaierU, AltinerA, HoffmannW, KilimannI (2017) Hippocampus and basal forebrain volumetry for dementia and mild cognitive impairment diagnosis: Could it be useful in primary care?J Alzheimers Dis55, 1379–1394.
17.
TeipelSJ, KilimannI, ThyrianJR, KlöppelS, HoffmannW (2017) Potential role of neuroimaging markers for early diagnosis of dementia in primary care. Curr Alzheimer Res14, 10.
18.
KilimannI, ThyrianJR, HoffmannW, TeipelSJ (2017) Translation of imaging biomarkers from clinical research to healthcare, Z Gerontol Geriatr50, 84–88.
19.
TeipelS, DrzezgaA, GrotheMJ, BarthelH, ChetelatG, SchuffN, SkudlarskiP, CavedoE, FrisoniGB, HoffmannW, ThyrianJR, FoxC, MinoshimaS, SabriO, FellgiebelA (2015) Multimodal imaging in Alzheimer’s disease: Validity and usefulness for early detection. Lancet Neurol14, 1037–1053.
20.
ThyrianJR, FissT, DreierA, BowingG, AngelowA, LuekeS, TeipelS, FlessaS, GrabeHJ, FreybergerHJ, HoffmannW (2012) Life- and person-centred help in Mecklenburg-Western Pomerania, Germany (DelpHi): Study protocol for a randomised controlled trial. Trials13, 56.
21.
ThyrianJR, HertelJ, WuchererD, EichlerT, MichalowskyB, Dreier-WolfgrammA, ZwingmannI, KilimannI, TeipelS, HoffmannW (2017) Effectiveness and safety of dementia care management in primary care: A randomized clinical trial. JAMA Psychiatry74, 996–1004.
22.
ThyrianJR, EichlerT, MichalowskyB, WuchererD, ReimannM, HertelJ, RichterS, DreierA, HoffmannW (2016) Community-dwelling people screened positive for dementia in primary care: A comprehensive, multivariate descriptive analysis using data from the DelpHi-Study. J Alzheimers Dis52, 609–617.
23.
ThyrianJR, HoffmannW (2012) Dementia care and general physicians-a survey on prevalence, means, attitudes and recommendations. Cent Eur J Public Health20, 270–275.
EichlerT, ThyrianJR, HertelJ, RichterS, MichalowskyB, WuchererD, DreierA, KilimannI, TeipelS, HoffmannW (2018) Patient variables associated with the assignment of a formal dementia diagnosis to positively screened primary care patients. Curr Alzheimer Res15, 7.
26.
EichlerT, ThyrianJR, HertelJ, MichalowskyB, WuchererD, DreierA, KilimannI, TeipelS, HoffmannW (2015) Rates of formal diagnosis of dementia in primary care: The effect of screening, Alzheimers Dement (Amst)1, 87–93.
27.
EichlerT, ThyrianJR, HertelJ, KöhlerL, WuchererD, DreierA, MichalowskyB, TeipelSJ, HoffmannW (2014) Rates of formal diagnosis in people screened positive for dementia in primary care: Results of the DelpHi-Trial, J Alzheimers Dis42, 451–458.
